- Datum04.12.2024
- Uhrzeit15:00 - 15:30 Uhr
- Veranstalterstock3
Mesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N. Chart
Du willst selbst ins Charting einsteigen?
Nutze das Charting-Widget auf dem stock3 Terminal für Deine eigene Analyse. Mehr Features. Mehr Werkzeuge. Mehr stock3.
Chart im Terminal öffnenMesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N. Realtime-Kurs
Name | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
---|---|---|---|---|---|---|
Baader | VK | |||||
gettex | VK | |||||
Nasdaq | VK |
Passende Produkte
WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
---|
Wertentwicklung (Nasdaq)
Wikifolio
Passender Service zu Mesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N.
Webinar zu Mesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,010-12,179
- Jahrestief / Hoch ($)1,010-12,179
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Mesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N.
Termine von Mesoblast Ltd. Reg.Shares(Sp.ADRs 144A)5 o.N.
Beschreibung
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.